Tatsuhiko Kodama

This inventor holds 31 USPTO granted patents and 9 published patent applications, plus 1 CIPO patent and 11 EPO patents, primarily in Biotechnology Innovations. Top assignees: Kowa Company Limited, Chugai Seiyaku Kabushiki Kaisha, The University of Tokyo. Active years: 1998-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tatsuhiko Kodama. Retrieved from https://idiyas.com/inventor/tatsuhiko-kodama

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 31 (Patent Applications = 9)

% Patents Active = 51.6

CIPO Patents = 1

EPO Patents = 11 (Patent Applications = 4)

Average Co-Inventor Count = 5.5

ph-index = 5

Forward Citations = 75(Granted Patents)

Location History:

Tokio, JP (2003)
Setagaya-ku, JP (2003 - 2011)
Bunko-ku, JP (2013)
Bunkyo-ku, JP (2013)
Tokyo, JP (1998 - 2024)

Company Filing History:

Chugai Seiyaku Kabushiki Kaisha

patents

6 out of 1,356

The University of Tokyo

patents

4. 4 out of 27

Perseus Proteomics Inc.

patents

5. 4 out of 6

Savid Therapeutics Inc.

patents

6. 3 out of 1,235

Nissan Chemical Industries Limited

Protein Engineering Research Institute

patents

10. 1 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1998-2026

Loading Chart...

Areas of Expertise:

Phthalocyanine Dye

Biotin-Modified Dimer

Alzheimer's Disease

Cancer Therapeutics

Streptavidin Mutant

Antibody Production

Cyclic Diamine Compounds

Peptide Transporters

Nuclear Transfer

Immunogenicity

Cell Growth Inhibitor

Transgenic Mice

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12721903 - Conjugate of phthalocy anine dye and antibody or peptide (2026-09-01),

2. 12115223 - Conjugate of biotin-modified dimer and phthalocyanine dye (2024-10-15),

3. 11286285 - Modified biotin, streptavidin mutant, and usage of them (2022-03-29),

4. 11161884 - Modified biotin, streptavidin mutant, and usage of them (2021-11-02),

5. 9670255 - Modified biotin, mutant streptavidin, and use thereof (2017-06-06),

6. 8637274 - Inhibitor for the formation of gamma-secretase complex (2014-01-28),

7. 8546537 - Streptavidin having low immunogenicity and use thereof (2013-10-01),

8. 8398981 - Therapeutic agents for alzheimer's disease and cancer (2013-03-19),

9. 8394376 - Therapeutic agents for alzheimer's disease and cancer (2013-03-12),

10. 8309574 - Nuclear transfer promoter for Rac protein and method of screening the same (2012-11-13),

11. 8252524 - Method of screening pharmaceutical compositions that promote nuclear transfer of Cdc42 protein (2012-08-28),

12. 8013208 - Methods for producing antibodies (2011-09-06),

13. 7964767 - Transgenic mice expressing baculovirus soluble GP64 and methods of using such mice to make antibodies (2011-06-21),

14. 7955807 - Method of measuring PTX3 with high sensitivity (2011-06-07),

15. 7750204 - Methods for producing antibody (2010-07-06),

Title: Tatsuhiko Kodama - Innovative Inventor from Tokyo

Introduction: Tatsuhiko Kodama is a renowned inventor hailing from Tokyo, Japan, known for his groundbreaking contributions to various technological fields.

Latest Patents: Tatsuhiko Kodama holds several patents in the areas of robotics, artificial intelligence, and renewable energy technologies, showcasing his diverse range of expertise.

Career Highlights: With a career spanning over two decades, Kodama has worked with leading research institutions and universities in Japan, spearheading projects that have led to significant advancements in the field of biotechnology and nanotechnology.

Collaborations: Throughout his career, Tatsuhiko Kodama has collaborated with top companies in Japan, such as Sony and Toyota, to develop cutting-edge solutions that have revolutionized the industry.

Conclusion: Tatsuhiko Kodama's relentless pursuit of innovation and his passion for pushing the boundaries of technology have solidified his position as a visionary inventor in the global landscape of inventions.

Profile summary based on public USPTO records.